Infectious disease biotechnology company Alopexx (ALPX.US) doubles IPO size, planning to raise $33 million.

Focused on developing immunotherapies for bacterial, fungal, and parasitic infections, the biotechnology company Alopexx (ALPX.US) in the clinical stage of drug development increased the proposed size of its upcoming initial public offering (IPO) last Friday. The company, headquartered in Cambridge, Massachusetts, now plans to issue 3 million shares of stock at a price range of $10 to $12 per share, raising $33 million in funds. The company had previously applied in September 2024 to issue 2.4 million shares at a price of $5 per share. Alopexx initially submitted its application in March 2022 and finalized the terms of the offering in August 2022. Based on the revised terms, the raised funds for Alopexx will increase by 175% compared to the initial expectations, with a fully diluted market value of $102 million (a 175% increase from the previous terms). Alopexx's lead drug candidate F598 has completed phase I clinical trials and initial phase II trials, showing good tolerability with no serious adverse reactions. The drug provides immediate protection for two to three months with a single dose. The company plans to conduct clinical trials of F598 for critically ill patients in intensive care units (ICUs) with high rates of hospital-acquired infections, aiming to establish it as a standard treatment for prevention and improvement of infections caused by Gram-negative bacteria, Gram-positive bacteria, and fungi. Another investigational drug by Alopexx is the synthetic PNAG vaccine AV0328, which has also completed phase I clinical trials. Studies have shown that the vaccine can induce the production of antibodies in the human body and kill a variety of pathogens expressing PNAG; in vitro experiments have demonstrated efficacy against more than ten microbial strains. In addition to infectious diseases, the company believes that both drugs can also be applied to neurological diseases, including Alzheimer's disease and traumatic brain injury. Research suggests that microbial fragments containing PNAG can trigger chronic inflammation, leading to cognitive decline, and these drugs are expected to play a role in treating such conditions. Founded in 2006, Alopexx plans to list on the NYSE American under the ticker symbol "ALPX." ThinkEquity is serving as the sole book-running manager for this transaction.